ABS Stenting System - Drug Eluting Stent
Pre-clinical- Indications
- Coronary artery disease, Bifurcation disease
Company intelligence / Profile preview
The ABS System is a proprietary stent delivery platform designed to simplify and improve the treatment of coronary bifurcation lesions. It has completed first-in-human trials in 10 patients across three international centers with 100% technical success and excellent one-year follow-up results. The product has received FDA Breakthrough Device Designation as of October 2023, with regulatory pathways defined for further clinical development and commercialization.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Advanced Bifurcation Systems.